Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762839 | 0.88 | PPARG (0.39) | TSHRRAB9AL3MBTL1PPARGALDH1A1 | |
| SCHEMBL1762597 | 0.81 | SMN1; SMN2 (0.39) | PPARGALDH1A1LMNAHPGDCYP11B1 | |
| SCHEMBL1762466 | 0.79 | KMT2A (0.43) | TSHRALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL1762635 | 0.78 | TUBB1 (0.43) | TSHRRAB9AALDH1A1LMNAHPGD | |
| SCHEMBL1762893 | 0.78 | PTK2 (0.39) | RAB9AL3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL1762561 | 0.77 | TACR3 (0.46) | — | |
| SCHEMBL1763005 | 0.77 | MEN1 (0.37) | ALDH1A1LMNAHPGDCYP11B1CYP11B2 | |
| SCHEMBL1762713 | 0.77 | DGAT1 (0.42) | ALDH1A1LMNAHPGD | |
| SCHEMBL1762469 | 0.76 | HCRTR1 (0.39) | ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL1762569 | 0.76 | TUBB1 (0.39) | HTR1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633193-B2 | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-05-19 | — | — | US | disclosed |
| US-7906528-B2 | Such as 5-(2,6-diethyl-phenyl)-1H-pyrrolo[2,3-C]pyridine, which binds C5a receptors with high affinity; for treatment of inflammatory, cardiovascular, and immune system disorders; kits | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-15 | — | — | US | disclosed |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | NEUROGEN CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | C5AR1, C5AR2, C3AR1 | TSHR 246/4885RAB9A 2323/4885L3MBTL1 4373/4885 |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | C5AR1, C5AR2, C3AR1 | TSHR 246/4885RAB9A 2323/4885L3MBTL1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.